A Phase 4 interventional study of Clopidogrel and Aspirin in Ischemic Cerebrovascular Accident, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-02-12.
Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment
Evaluate the role of loading Clopidogrel in acute ischemic stroke in improving neurological outcome of stroke in cases patients will be non-eligible for, or declined, treatment with or intravenous thrombolysis with rTPA, rTPA is not available or thrombectomy.
7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.
This study's enrollment of 188 is above the median of 50 across 5,369 interventional studies indexed under Stroke.
Browse Stroke studies →Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients receiving anti-coagulants in deep venous thrombosis (DVT) prophylaxis doses will NOT be excluded:
Urgent brain CT revealing any of the following:
67 patients will receive 12 tablets clopidogrel ( each 75 mg) as total 900 mg each patient
Drug: Clopidogrel
67 patient will receive 8 tablets clopidogrel (each 75 mg) as total 600 mg each patient and 4 tablets placebo to receive 12 tablets as total
Drug: Clopidogrel
67 patients will receive 4 tablets Aspirin ( each 75 mg) as total 300 mg for each patient and 8 tablets placebo to receive 12 tablets as total
Drug: Aspirin
there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel
Also known as: Srtoka
there's another group will receive 400 mg Aspirin
Also known as: Aspocid
The change of NIH stroke scale score
Patients will be assessed for early neurologic improvement or deterioration using the change of NIH stroke scale score. Early neurological outcome
Time frame: Baseline and up to 1 week
Neurologic outcome
patients will be assessed for neurologic outcome using the Modified Ranking Scale at 3 months after onset
Time frame: 3 months
Bleeding complications of loading clopidogrel
will follow cerebral bleeding complications using CT scan, and systemic bleeding complications (GI bleeding, hematuria, etc.) that may occur following the loading dose
Time frame: 1 week
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ain Shams University